MiR-26a在肺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2019.06.017

摘要/Abstract

摘要： 肺癌的发病和死亡居全部恶性肿瘤的首位,同时肺癌患者的耐药情况愈来愈严峻,给国家经济和人民健康造成了极大负担。MiR-26a是一类小的非编码RNA,通过靶向调控相关蛋白与信使RNAs(mRNAs)而影响肺癌细胞的增殖、迁移和侵袭等生物学作用。本文旨在对miR-26a在肺癌中的作用机制进行详细阐述,为肺癌的治疗与耐药提供临床生物标志物。

关键词: MiR-26a, 肺癌, 生物学标志物

Abstract: The incidence and death of lung cancer rank first among all malignant tumors,and drug resistance of lung cancer patients is becoming more and more severe,which has caused a great burden on the national economy and people′s health.MiR-26a is a small class of non-coding RNA that affects the biological effects on proliferation,migration and invasion of lung cancer cells by targeting related proteins and messenger RNAs(mRNAs).This article aims to elaborate the mechanism of miR-26a in lung cancer and provides the clinical biomarkers for the treatment and drug resistance of lung cancer.

Key words: MiR-26a, Lung cancer, Biomarker

中图分类号:

R734.2

王静西, 董晓平, 张雪, 贺宇彤. MiR-26a在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 561-565.

WANG Jingxi, DONG Xiaoping, ZHANG Xue, HE Yutong. Research progress of MiR-26a in lung cancer[J]. Journal of Practical Oncology, 2019, 33(6): 561-565.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.06.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I6/561

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 朱晓云,张亚宁,林菲,等.上海市金山区2002-2013年肺癌发病及死亡分析[J].实用肿瘤学杂志,2018,32(5):437-441.
3 Wang L,Yu C,Liu Y,et al.Lung cancer mortality trends in China from 1988 to 2013:new challenges and opportunities for the government[J].Int J Environ Public Health,2016,13(11):1052.
4 Seder CW,Kubasiak JC,Pithadia R,et al.Angiogenesis biomarkers may be useful in the management of patients with indeterminate pulmonary nodules[J].Ann Thorac Surg,2015,100(2):429-436.
5 Vazquez M,Carter D,Brambilla E,et al.Solitary and multiple resected adenocarcinomas after CT screening for lung cancer:histopathologic features and their prognostic implications[J].Lung Cancer,2009,64(2):148-154.
6 Bartel DP.MicroRNAs:genomics,biogenesis,mechanism,and function[J].Cell,2004,116(2):281-297.
7 Chen J,Zhang K,Xu Y,et al.The role of microRNA-26a in human cancer progression and clinical application[J].Tumour Biol,2016,37(6):7095-7108.
8 Erdmann K,Kaulke K,Rieger C,et al.MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells[J].J Cancer Res Clin Oncol,2016,142(11):1-13.
9 Shao Y,Li P,Zhu ST,et al.MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2[J].Oncotarget,2016,7(12):15173-15186.
10 Li J,An G,Zhang M,et al.Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells[J].Biochem Biophys Res Commun,2016,477(4):743-748.
11 Sekimoto N,Suzuki A,Suzuki Y,et al.Expression of miR26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells[J].Mol Med Rep,2017,15(2):534-542.
12 Wang Y,Hou N,Cheng X,et al.Ezh2 acts as a tumor suppressor in kras-driven lung adenocarcinoma[J].Int J Biol Sci,2017,13(5):652-659.
13 Dang X,Ma A,Yang L,et al.MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells[J].Cancer Genet,2012,205(3):113-123.
14 高阳,陈红.MiR-26a与EZH2蛋白的关系及其对肺癌细胞的增殖和凋亡行为的影响[J].解放军医药杂志,2018,30(1):27-30.
15 Zhang X,Xiao D,Wang Z,et al.MicroRNA-26a/b regulate DNA replication licensing,tumorigenesis,and prognosis by targeting CDC6 in lung cancer[J].Mol Cancer Res,2014,12(11):1535-1546.
16 Guan X,Fang Y,Long J,et al.Annexin 1-nuclear factor-κB-microRNA-26a regulatory pathway in the metastasis of non-small cell lung cancer[J].Thorac Cancer,2019,10(4):665-675.
17 Chen X,Guan X,Zhang H,et al.DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer[J].J Exp Clin Cancer Res,2015,34:3.
18 Cai T,Guan X,Wang H,et al.MicroRNA-26a regulates ANXA1,rather than DAL-1,in the development of lung cancer[J].Oncol Lett,2018,15(4):5893-5902.
19 Ye Y,Tang X,Sun Z,et al.Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth,migration,and invasion[J].Oncotarget,2016,7(14):17854-17869.
20 Yakisich JS,Azad N,Venkatadri R,et al.Formation of tumorspheres with increased stemness without external mitogens in a lung cancer model[J].Stem Cells Int,2016,2016:5603135.
21 Shahriari S,Rezaeifard S,Moghimi HR,et al.Cell membrane and intracellular expression of toll-like receptor 9(TLR9)in colorectal cancer and breast cancer cell-lines[J].Cancer Biomarkers,2017,18(4):1-6.
22 Lai YH,Liu HY,Huang CY,et al.Mitochondrial-DNA-associated TLR9 signalling is a potential serological biomarker for non-small cell lung cancer[J].Oncol Rep,2019,41(2):999-1006.
23 Jiang DS,Wang YW,Jiang J,et al.MicroRNA-26a involved in Toll-like receptor 9mediated lung cancer growth and migration[J].Int J Mol Med,2014,34(1):307-312.
24 Lin G,Liu B,Meng Z,et al.MiR-26a enhances invasive capacity by suppressing GSK3beta in human lung cancer cells[J].Exp Cell Res,2017,352(2):364-374.
25 Ulivi P,Petracci E,Marisi G,et al.Prognostic role of circulating miRNAs in early-stage non-small cell lung cancer[J].J Clin Med,2019,8(2):2077-0383.
26 Gallach S,Jantus LE,Calabuig FS,et al.MicroRNA profiling associated with non-small cell lung cancer:next generation sequencing detection,experimental validation,and prognostic value[J].Oncotarget,2017,8(34):56143-56157.
27 Liu B,Wu X,Liu B,et al.MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN[J].Biochim Biophys Acta,2012,1822(11):1692-1704.
28 Tong L,Luo Y,Wei T,et al.KH-type splicing regulatory protein(KHSRP)contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer[J].Mol Cell Biochem,2016,422(1/2):61-74.
29 Heineman DJ,Daniels JM,Schreurs WH.Clinical staging of NSCLC:current evidence and implications for adjuvant chemotherapy[J].Ther Adv Med Oncol,2017,9(9):599-609.
30 Yang Y,Zhang P,Zhao Y,et al.Decreased microRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer[J].Cancer Biol Ther,2016,17(5):515-525.
31 Zhong J,Li L,Wang Z,et al.Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)[J].J Thorac Oncol,2017,12(12):1766-1778.
32 Lim SM,Syn NL,Cho BC,et al.Acquired resistance to EGFR targeted therapy in non-small cell lung cancer:Mechanisms and therapeutic strategies[J].Cancer Treat Rev,2018,65:1-10.
33 Lee CK,Kim S,Lee JS,et al.Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs[J].Lung Cancer,2017,113:106-114.
34 Xu S,Wang T,Yang Z,et al.MiR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13[J].Oncotarget,2016,7(29):45687-45701.
35 Chen J,Xu Y,Tao L,et al.MiRNA-26a contributes to the acquisition of malignant behaviors of doctaxel-resistant lung adenocarcinoma cells through targeting EZH2[J].Cell Physiol Biochem,2017,41(2):583-597.

[1]	孙亦鹏, 倪振华, 吴颖颖, 陈清阁, 毕俊杰, 林玉华, 王雄彪. 过表达CLPTM1L降低95-D肺癌细胞对吉西他滨的敏感性[J]. 实用肿瘤学杂志, 2019, 33(6): 486-490.
[2]	李传海, 刘玉, 王延群, 陈英剑. ABL2在肺癌中的作用及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 497-501.
[3]	李剑, 徐向英, 吕研. 局限期小细胞肺癌首程治疗失败后再程治疗的相关研究[J]. 实用肿瘤学杂志, 2019, 33(6): 519-524.
[4]	孙亚娟, 姜智允, 尚乃舰, 孙庆鑫, 陆佩欧. 双源CT能量成像在评估非小细胞肺癌纵隔淋巴结转移中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(6): 531-535.
[5]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[6]	刘金涛, 高玲, 周会会. MAGEA4和EB1蛋白在肺癌组织中的表达及其与临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(4): 334-339.
[7]	朱诗佳徐向英. 海马区保护治疗小细胞肺癌全脑照射的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 380-383.
[8]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[9]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[10]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[11]	张彦秋,韩阿蒙,李金旺,顾涛,付占昭,毛羽,张子健,杨振. CRT+ARC技术在局部晚期肺癌患者中临床应用的初步研究[J]. 实用肿瘤学杂志, 2019, 33(3): 256-260.
[12]	赵苏, 郑晓瑜, 朱开彬, 卜建龙, 徐世东. 肺癌完全性切除术对患者外周血中Th17/Treg细胞平衡的影响[J]. 实用肿瘤学杂志, 2019, 33(2): 142-148.
[13]	胡智慧综述, 张静审校. SNP对放射性肺损伤预测作用的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 87-91.
[14]	迪娜·木拉力, 胡昕综述, 加孜那·托哈依审校. 远程医疗在肺癌中的应用及前景[J]. 实用肿瘤学杂志, 2018, 32(6): 555-557.
[15]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.